ALLO-501 + ALLO-647

ALLO-501 + ALLO-647 is a combination investigational therapy for hematologic malignancies, specifically relapsed/refractory large B-cell lymphoma and follicular lymphoma. ALLO-501 is an allogeneic (off-the-shelf) anti-CD19 Chimeric Antigen Receptor (CAR) T cell therapy engineered using gene editing to disrupt the TCR alpha constant (TRAC) gene (to prevent graft-versus-host disease) and the CD52 gene (to permit the use of ALLO-647). ALLO-647 is an anti-CD52 monoclonal antibody administered alongside ALLO-501 as part of the lymphodepletion regimen before CAR-T infusion, enabling selective and prolonged host immune cell depletion to allow CAR-T cell persistence and activity. This combination leverages gene editing and antibody-mediated depletion for improved safety, feasibility, and potential efficacy over autologous CAR T approaches[1][5][7].